How Long to Lose Weight on Wegovy: A Comprehensive Guide

Last reviewed: July 1, 2026

Last updated: July 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The pivotal trials measured Wegovy's weight effect over 68 to 72 weeks — roughly sixteen months — and that is the honest frame for "how long." In STEP 1, mean body weight change at week 68 was −14.9% with once-weekly semaglutide 2.4 mg versus −2.4% with placebo. That figure is an endpoint, not a milestone reached early and then held. Weight came down across the full study period, most steeply in the middle months and progressively more slowly toward the end. Anyone quoting a tidy number for twelve weeks is extrapolating, because the trials were not designed to answer at twelve weeks.

What the Trials Measured, and Over How Long

STEP 1 enrolled 1,961 adults with a body mass index of 30 or greater, or 27 or greater with at least one weight-related coexisting condition, none of whom had diabetes. They were randomized 2:1 to 68 weeks of semaglutide 2.4 mg or placebo, both with lifestyle intervention. Absolute weight change was −15.3 kg versus −2.6 kg, an estimated treatment difference of −12.7 kg.

The higher-dose program ran slightly longer. STEP UP randomized 1,407 adults with a BMI of 30 or above and without diabetes, in a 5:1:1 ratio, to 72 weeks of semaglutide 7.2 mg, 2.4 mg, or placebo. Mean weight change was −18.7% at 7.2 mg, −15.6% at 2.4 mg, and −3.9% on placebo. Mean baseline weight was 113.0 kg and mean BMI 39.9. The 7.2 mg strength is now the labeled maximum for the injection, marketed as Wegovy HD.

The Label Frames This as Long-Term Treatment

Wording matters here. The Wegovy prescribing information indicates the injection, in combination with a reduced-calorie diet and increased physical activity, "to reduce excess body weight and maintain weight reduction long term" in adults and pediatric patients aged 12 and older with obesity, or adults with overweight plus at least one weight-related comorbid condition. It also carries indications for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, and for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis.

"Maintain weight reduction long term" is not filler. It signals that the approved use is chronic management rather than a defined course with an end date, which reframes the question from "how long until I finish" to "how long until the trajectory is established, and what happens after."

An Intermediate Marker Around Five Months

The clearest published mid-course number comes from STEP 4, which used a 20-week run-in — 16 weeks of dose escalation plus four weeks at the maintenance dose — before randomizing participants. Across 902 participants, that run-in produced a mean weight loss of 10.6%, and 803 participants (89.0%) reached the 2.4 mg maintenance level.

Two things follow. First, a meaningful share of total weight change occurred in the first five months, so early progress is not unusual. Second, that period included the entire escalation phase, which means the trajectory during it was not driven by a steady dose. Reading a personal four-week result as a prediction of week 68 is a mistake in both directions.

Averages Hide a Wide Distribution

STEP 1 reported responder rates alongside the mean, and they are the more useful statistic for an individual. At week 68, weight reductions of at least 5% were achieved by 1,047 semaglutide participants (86.4%) versus 182 on placebo (31.5%); at least 10% by 838 (69.1%) versus 69 (12.0%); and at least 15% by 612 (50.5%) versus 28 (4.9%).

So about half the treated group crossed 15% and about half did not. STEP UP found the same pattern at a higher dose: participants on 7.2 mg were more likely than those on 2.4 mg to reach reductions of at least 20% and at least 25%, but "more likely" describes odds across a group. Where any one person lands within that spread is not knowable in advance, and it is not a measure of effort.

Why Weight Loss Slows Down

Deceleration is expected, not a malfunction. A smaller body burns fewer calories at rest and during movement, so the same intake that produced a deficit at the start produces a smaller one later. Appetite regulation also adapts over time. The result in every long pharmacotherapy trial is a curve that flattens rather than a straight line.

This is where body composition deserves attention. Rapid weight loss draws on lean mass as well as fat, and lean mass is metabolically active tissue you generally want to keep. Adequate protein intake and resistance training are the levers with the best evidence behind them for shifting the composition of what is lost, and they cost nothing in medication terms.

Staying On It Is a Separate Question From Getting There

STEP 4 tested this directly. Participants who completed the 20-week run-in were randomized 2:1 to 48 further weeks of semaglutide or to placebo, plus lifestyle intervention. Mean body weight change from week 20 to week 68 was −7.9% with continued semaglutide versus +6.9% after the switch to placebo — a difference of −14.8 percentage points. Waist circumference and systolic blood pressure moved with it.

The STEP 1 extension looked further out. Among 327 participants followed for a year after all treatment and lifestyle intervention stopped, a mean 17.3% weight loss at week 68 was followed by regain of 11.6 percentage points by week 120, leaving a net 5.6% below baseline. Most cardiometabolic improvements reverted toward baseline. The investigators concluded that obesity is chronic and that ongoing treatment is required to maintain the gains.

What Actually Changes Your Personal Timeline

Adherence dominates. A 2026 narrative review of real-world persistence with GLP-1-based therapies found persistence ranging from roughly 75–80% at 12 months in reimbursed diabetes cohorts down to below 10% in obesity-focused or high out-of-pocket settings, with gastrointestinal intolerance and cost identified as the primary drivers of discontinuation. Real-world results lag trial results largely because people stop.

Tolerability is part of that picture. In STEP 1, 4.5% of the semaglutide group discontinued because of gastrointestinal events versus 0.8% on placebo, and in STEP UP gastrointestinal adverse events were reported in 70.8% at 7.2 mg versus 61.2% at 2.4 mg and 42.8% on placebo. Baseline weight, other medical conditions, sleep, alcohol, and the quality of the surrounding nutrition and activity plan all shift the curve as well.

None of that translates into a dose, a schedule, or a target date you should set for yourself. Questions about how a regimen progresses, how long to continue, and what to do if progress stalls are individual clinical judgments that belong to your prescriber, informed by your pharmacy label and your own measured response.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How long did it take to reach maximum weight loss in the Wegovy trials?

STEP 1 measured its primary endpoint at week 68, roughly sixteen months, reporting a mean body weight change of −14.9% with semaglutide 2.4 mg versus −2.4% with placebo. The higher-dose STEP UP trial ran 72 weeks and reported −18.7% at semaglutide 7.2 mg, −15.6% at 2.4 mg, and −3.9% on placebo. Weight continued to fall through most of both study periods.

How much weight had people lost after about five months?

The clearest published figure comes from STEP 4, whose 20-week run-in period produced a mean weight loss of 10.6% across 902 participants. That run-in comprised 16 weeks of dose escalation plus four weeks at the maintenance dose, so it captures the full early phase. It is a group average from a supervised trial and should not be read as a personal target or forecast.

Does everyone lose the same amount?

No, and the spread is wide. At week 68 in STEP 1, 86.4% of the semaglutide group had lost at least 5% of body weight, 69.1% at least 10%, and 50.5% at least 15%. Roughly half crossed the 15% threshold and roughly half did not. Where an individual lands within that distribution cannot be predicted in advance and is not a measure of effort.

Why does my weight loss slow down over time?

A smaller body expends fewer calories at rest and in motion, so the same intake produces a shrinking deficit, and appetite regulation adapts as well. Every long pharmacotherapy trial shows a curve that flattens rather than a straight line. Protein intake and resistance training are the best-supported levers for preserving lean mass while weight comes down, which affects the composition of the loss.

Do I have to stay on it to keep the weight off?

The published evidence points that way. In STEP 4, weight changed −7.9% with continued semaglutide versus +6.9% after switching to placebo over 48 weeks. In the STEP 1 extension, participants regained 11.6 percentage points of a 17.3% mean loss within a year of stopping. How long to continue is a clinical decision for you and your prescriber, not a fixed rule.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.